STK11 and non-small cell lung carcinoma: More recently, a retrospective analysis in advanced NSCLC patients treated with first-line platinum-based chemotherapy with or without pembrolizumab revealed that patients with advanced LKB1-mutant non-squamous NSCLC do not achieve clinical benefit from pembrolizumab addition to chemotherapy.